Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
企業コードSPRC
会社名Scisparc Ltd
上場日Dec 22, 2021
最高経営責任者「CEO」Mr. Amitay Weiss
従業員数2
証券種類Ordinary Share
決算期末Dec 22
本社所在地20 Raul Wallenberg Street, Tower A
都市TEL AVIV-YAFO
証券取引所NASDAQ Capital Market Consolidated
国Israel
郵便番号6971916
電話番号97236103100
ウェブサイトhttps://scisparc.com/
企業コードSPRC
上場日Dec 22, 2021
最高経営責任者「CEO」Mr. Amitay Weiss
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし